Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Sichuan Kelun Pharmaceutical Co., Ltd.
  6. Summary
    002422   CNE100000PW7

SICHUAN KELUN PHARMACEUTICAL CO., LTD.

(002422)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
17.94 18.32 17.95 17.78 17.73 Last
11292310 13743360 31595250 17498390 10368370 Volume
+0.45% +2.12% -2.02% -0.95% -0.28% Change
Estimated financial data (e)
Sales 2022 18 841 M 2 790 M 2 790 M
Net income 2022 1 342 M 199 M 199 M
Net Debt 2022 9 928 M 1 470 M 1 470 M
P/E ratio 2022 18,8x
Yield 2022 1,75%
Sales 2023 21 060 M 3 118 M 3 118 M
Net income 2023 1 547 M 229 M 229 M
Net Debt 2023 9 429 M 1 396 M 1 396 M
P/E ratio 2023 16,4x
Yield 2023 2,41%
Capitalization 24 933 M 3 692 M 3 692 M
EV / Sales 2022 1,85x
EV / Sales 2023 1,63x
Nbr of Employees 19 031
Free-Float 57,4%
More Financials
Company
Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows: - manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.); - other (2%). China accounts for 94.6% of net sales. 
Read more
Sector
Pharmaceuticals
Calendar
08/31Earnings Release
More about the company
Ratings of Sichuan Kelun Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SICHUAN KELUN PHARMACEUTICAL CO., LTD.
05/17Kelun Pharma Licenses Cancer Drug to Merck Unit For Up to $1.4 Billion
MT
05/09Sichuan Kelun Pharmaceutical Co., Ltd. Announces Final Distribution for the Year 2021, ..
CI
05/06Sichuan Kelun Pharmaceutical Co., Ltd. Approves Dividend for 2021
CI
04/26Sichuan Kelun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million ..
CI
04/26Sichuan Kelun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
04/18Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter E..
CI
04/12Tranche Update on Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announce..
CI
04/12Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 30, 2021, has..
CI
04/11Kelun Pharmaceutical Lifts Final Dividend as 2021 Profit Jumps 33%
MT
04/11Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021
CI
03/16Sichuan Kelun Pharmaceutical to Sell $472 Million RMB Convertible Bonds
MT
02/22Chinese Regulators OK HBM's Investigational New Drug Application for Asthma Treatment; ..
MT
01/19Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 21, 2021, ..
CI
01/07Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended..
CI
01/05Tranche Update on Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announce..
CI
More news
News in other languages on SICHUAN KELUN PHARMACEUTICAL CO., LTD.
05/17Kelun Pharma accorde une licence pour un médicament contre le cancer à une unité de Mer..
05/09Sichuan Kelun Pharmaceutical Co., Ltd. annonce la distribution finale pour l'année 2021..
05/06Sichuan Kelun Pharmaceutical Co., Ltd. approuve le dividende pour 2021
04/26SICHUAN KELUN PHARMACEUTICAL CO., LT : 002422) annonce un rachat d'actions pour une valeur..
04/26Sichuan Kelun Pharmaceutical Co., Ltd. autorise un plan de rachat.
More news
Chart SICHUAN KELUN PHARMACEUTICAL CO., LTD.
Duration : Period :
Sichuan Kelun Pharmaceutical Co., Ltd. Technical Analysis Chart | 002422 | CNE100000PW7 | MarketScreener
Technical analysis trends SICHUAN KELUN PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 17,73 CNY
Average target price 20,28 CNY
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Si Chuan Liu Director & Deputy General Manager
De Gui Lai Chief Financial & Accounting Officer, Deputy GM
Ge Xin Liu Chairman
Peng Wan Legal Affairs Director
Yue Dong Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SICHUAN KELUN PHARMACEUTICAL CO., LTD.-6.34%3 711
JOHNSON & JOHNSON2.59%470 547
PFIZER, INC.-14.65%288 063
ABBVIE INC.12.58%273 513
ELI LILLY AND COMPANY6.87%271 308
ROCHE HOLDING AG-14.97%263 868